S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

$10.30
+0.63 (+6.51%)
(As of 02/26/2024 ET)
Today's Range
$9.88
$10.30
50-Day Range
$5.15
$13.10
52-Week Range
$5.00
$45.60
Volume
3,798 shs
Average Volume
11,200 shs
Market Capitalization
$10.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADXN stock logo

About Addex Therapeutics Stock (NASDAQ:ADXN)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ADXN Stock Price History

ADXN Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Addex to Present at Biotech Showcase™ 2024
Addex Therapeutics Ltd
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Addex Creates Treasury Shares
Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts
Addex Convenes Extraordinary General Meeting
Addex Therapeutics: Addex Completes ADS Ratio Change
Addex Completes ADS Ratio Change
Addex To Implement ADS Ratio Change
H.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/29/2023
Today
2/26/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXN
Employees
24
Year Founded
N/A

Profitability

Net Income
$-21,800,000.00
Net Margins
-550.78%
Pretax Margin
-549.49%

Debt

Sales & Book Value

Annual Sales
$1.51 million
Book Value
$8.01 per share

Miscellaneous

Free Float
843,000
Market Cap
$9.79 million
Optionable
Not Optionable
Beta
1.65
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy Mark Dyer (Age 56)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 67)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 38)
    Head of Finance
  • Dr. Jean-Philippe Rocher Ph.D. (Age 65)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 56)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 57)
    Head of Translational Science














ADXN Stock Analysis - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

How have ADXN shares performed in 2024?

Addex Therapeutics' stock was trading at $6.05 at the beginning of 2024. Since then, ADXN stock has increased by 63.5% and is now trading at $9.89.
View the best growth stocks for 2024 here
.

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 8,700 shares, an increase of 222.2% from the January 15th total of 2,700 shares. Based on an average trading volume of 10,800 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the company's stock are short sold.
View Addex Therapeutics' Short Interest
.

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ADXN earnings forecast
.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings data on Wednesday, November, 29th. The company reported ($4.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.00) by $0.07. The business had revenue of $0.37 million for the quarter, compared to the consensus estimate of $0.70 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%.

When did Addex Therapeutics' stock split?

Shares of Addex Therapeutics reverse split on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

Who are Addex Therapeutics' major shareholders?

Addex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include J. Stern & Co. LLP (10.89%) and Armistice Capital LLC (4.34%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXN) was last updated on 2/26/2024 by MarketBeat.com Staff